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THE mutual correlation among soluble CD4
(sCD4), soluble CD8 (sCD8), and soluble CD23
(sCD23) has not yet been studied in patients with
rheumatoid arthritis (RA), although previous
studies have demonstrated that certain soluble
markers of immune activation are elevated in RA.
Thus, we examined this correlation based on the
serum levels of sCD4, sCD8 and sCD23, and that
of their levels with other serum markers such as
immunoglobulin (Ig) subtypes (IgG, IgM and IgA),
IgM-rheumatoid factor (IgM-RF) and C-reactive
protein (CRP) in 25 RA patients, sCD4 was not
elevated, whereas both sCD8 and sCD23 increased
in RA patients compared with the healthy
controls; a majority of RA patients, in particular,
showed a high sCD23 level. The level of sCD23
showed a correlation with that of IgM-RF, but not
with those of IgG, IgM, IgA and CRP. Importantly,
a high level of sCD23 was not always accom-
partied with that of sCD8. The independent
change between sCD23 and sCD8 levels was also
observed in a one-year follow-up study of the two
RA patients. These findings indicate that B cells
might be generally activated in RA, whereas T-cell
activation in variable in each patient with RA,
suggesting that sCD23 is a more indicative
marker for the immune status ofRA patients than
sCD8 from the clinical aspects.
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Introduction
Rheumatoid arthritis (RA) is a complex inflam-
matory disease of unknown cause and an auto-
immune phenomenon is strongly suspected. 1’2
Previous studies have described the significant
role of both T-cells and pro-inflammatory cyto-
kines such as interleukin (IL)-I, IL-6 and tumour
necrosis factor-z (TNF-00 in RA.-5 In addition, B
cells in the rheumatoid synovium are believed to
produce the rheumatoid factor (RF), of which
controlled mechanisms are still unclear.6 Similar
to systemic lupus erythematosus, serum soluble
CD8 (sCD8), soluble CD23 (sCD23) and soluble
IL-2 receptor have been shown to become ele-
vated in RA,7-9 Because these molecules are
recognized as being involved in T- and B-cell
functions,1’11 it is likely that the immune activa-
tion contributes in part to the pathogenesis of
RA. However, a mutual correlation among the
serum levels of these molecules has not yet been
clarified in RA. Thus, we examined this issue
based on the serum levels of sCD4, sCD8, and
sCD23/(low-affinity receptor for the Fc portion
of IgE), and their correlation with .other serum
markers such as immunoglobulin (Ig) subtypes
(IgG, IgM and IgA), IgM-rheumatoid factor (IgM-
RF) and C-reactive protein (CRP) in addition to
erythrocyte segmentation rate (ESR) in 25 RA
patients. Furthermore, a longitudinal comparison
in the changes in the serum levels of certain
soluble markers was performed.
Materials and Methods
Twenty-five patients (19 females and six
males) with flares of RA as defined by the revised
criteria of the American College of Rheumatol-
ogy
12 were included in this study. Characteristics
of these patients were as follows: mean _
SD
age 58.3 4- 13.5 years (range 22-76 years), mean
4- SD disease duration 8.5 4- 6.4 years (range
1-25 years), mean 4- SD ESR 81 ___
43 mm/h
(range 35-115 l.tm/h), mean ___
SD CH50 37.8 _+
7.1 mg/dl (range 26-53 mg/dl), anatomical stage
2.4 4- 1.2 and functional class 2.1 4- 0.9. All
were receiving non-steroidal anti-inflammatory
drugs (NSAIDs). Two were also taking bucill-
amine, three gold salts, and four prednisolone
(PSL, 2.5-10 mg/day). None was receiving metho-
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FIG. 1. Comparisons of serum sCD4, sCD8 and sCD23 levels between 25 RA patients and 20 healthy controls. The levels of sCD4 (left
panel) were no different between RA and controls, whereas those of sCD23 (right panel) in RA patients were significantly elevated
compared with controls. Although no significant difference was obtained in the mean value of sCD8 levels between RA and controls
(middle panel), there was a tendency to show higher sCD8 levels in RA patients. The Mann-Whitney U-test was performed using the
StatView-J 4.02 program (Abacus Concept, CA, USA).
trexate. As a control, sera from 20 healthy and
age-matched volunteers (52.3 -t-_ 15.9 years) were A
used. sCD4, sCD8 and sCD23 levels were deter-
mined simultaneously in all serum samples as
described below.
Serum levels of the soluble markers were mea-
sured by antibody sandwich enzyme-linked
immunosorbent assay (ELISA) using commercial
kits (sCD8 and sCD23: T-cell Diagnostics, Inc.,
Cambridge, MA; sCD4: Boehringer Mannheim
Biochemica, Germany). These levels were
expressed as U/ml except for sCD4 which was
expressed as ng/ml based on the standard curve
prepared simultaneously using standard mole-
cules provided in each kit. The detection limits B
were 0.25 ng/ml, 50 U/ml and 15 U/ml for sCD4,
sCD8 and sCD23, respectively. Serum samples
were stored at-20C until use.
Table 1. Correlation of sCD23 with several sero-
logical markers
sCD23 Probability Spearman’s rank
versus correlation
coefficient
IgG 0.976 0.008
IgM 0.243 0.290
IgA 0.363 0.139
CRP* 0.608 0.089
ESR** O. 108 0.570
IgM-RF 0.005 0.505
*CRP: C-reactive protein, **ESR: erythrocyte segmentation
rate.
All data were collected in a computer database and
analysed using Spearman’s rank correlation in the StatView-
J 4.02 program.
i000-
"800
600
400
200
0 0 0
500 i000 1500 2000 2500 3000
sCD23 (U/ml)
400-
350- -. 300-
E
250-
O200_
150--
i00
50--
Oi
o
o o
o o o
500 10100 15100 20100 2500 30100
sCD23 (U/ml)
FIG. 2. Correlation of sCD23 with IgM-RF, or with sCD8 in 25
RA patients. Correlation between sCD23 and IgM-RF was ana-
lysed (A) as described in the legend for Fig. 1. The data were
summarized as follows: Spearman rank correlation coefficient: r
0.505, p- 0.0049; linear regression coefficient: r 0.614, p
0.0002; y-- O.2x + 20.053. Alternatively, the same analysis
was carried out between sCD23 and sCD8 (B). The data were
summarized as follows: Spearman’s rank correlation coefficient: r
0.261, p 0.200; linear regression coefficient: r- 0.326, p
0.112. As a result, a significant correlation was obtained in the
former analysis but not in the latter one.
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FIG. 3. The time-related changes in the serum sCD23 level and other parameters (sCD8, IgM-RF, CRP and ESR) in two RA patients
during one year. Study periods were from June 1994 to July 1995 for Case (M.O., female, aged 70 years) with RA since 1968 (A),
and from July 1994 to June 1995 for Case 2 (M.N., female, aged 59 years) with RA since 1993 (B). In both cases, levels of sCD23
and sCD8 were measured simultaneously in the sera which were stored at -20C.
Results and Discussion
As shown in Fig. 1, the serum level of sCD4
showed no significant difference between RA
patients and healthy controls, but that of sCD23
was significantly higher in all RA patients com-
pared with controls. Concerning sCD8, these
values were distributed in a wider range with a
tendency that the majority of RA patients showed
higher ones which were, as a whole, statistically
no different from the controls. When the correla-
tion of the level of sCD23 with that of each Ig
subtype, CRP, or ESR was examined (Table 1),
no correlation was obtained between sCD23 and
each Ig subtype, or between sCD23 and CRP.
However, an insignificant but considerable corre-
lation was shown between sCD23 and ESR. Con-
sidering the fact that CRP is well known as a
more acute phase reactant than ESR, this finding
suggests that the serum level of sCD23 might be
taken as a parameter reflecting the immune acti-
vation in the chronic phase rather than the acute
phase. On the other hand, the correlation
between serum levels of sCD23 and IgM-RF was
statistically significant (Fig. 2A). These data
confirm that sCD23 might play an important role
on the specific production of IgM from RF-com-
mitted B cells.
A recent study has revealed that the sCD23
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molecule is not only a soluble activation marker,
but also a proinflammatory cytokine achieving an
important role in the control of the immune
response including T-cell response. Thus, we
further investigated the relationship between
sCD23 and sCD8. As shown in Fig. 2, a correla-
tion was not shown between these two mole-
cules, indicating that B cells might be activated.
generally in RA, whereas the degree of T-cell acti-
vation varies patient by patient in RA. Thus, it is
likely that a higher level of sCD23 in RA patients
does not always lead to the T-cell activation. The
analysis of the relation between sCD23 and sCD4
was not performed, because the normal level of
sCD4 was observed in RA (see Fig. 1).
We further performed a longitudinal study on
the changes in the serum sCD23, sCD8, and IgM-
RF levels in addition to classical inflammation
parameters (CRP and ESR) in two patients during
one year. The results are shown in Fig. 3. In both
cases, the serum levels of sCD23 were changing
almost in parallel with that’of IgM-RF.
Comparing both cases, a changing pattern of
sCD23 was correlated more closely to that of ESR
than CRP. In contrast, time-related change of the
serum level of sCD8 was also independent from
that of sCD23 in this study as shown in the
cross-sectional study described above. These
observations might permit speculation thatSoluble markers in rheumatoid arthritis
sCD23, but not sCD8, is taken as a more indica-
tive marker reflecting the immune status of RA
patients either in cross-section or longitudinal
study.
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